📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-08-07 19:31
395 analysed today
FollowTelegram
395
Today
149,796
All-time analysed
42,945
Positive
6,666
Negative
91,495
Neutral
8,622
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
22 announcements match the current filters (relevance ≥ 5).
18.9% Revenue Growth in Q1 FY27; Consolidated PAT Increases 24.6% YoY
CARE Ratings reported a consolidated operating income of ₹111.68 Cr for Q1 FY27, marking an 18.9% YoY increase. Consolidated PAT grew by 24.6% to ₹32.99 Cr, reflecting improved operational efficiency with an EBITDA margin of 31.0%. Despite a 29.3% decline in overall corporate bond issuances in the economy, the company's core ratings business grew 19.1% YoY, supported by strong bank credit growth of 18.6%. The non-ratings segment, including analytics and ESG, contributed ₹12.97 Cr to the top line.
Confidence: HIGH
What changedCARE Ratings has delivered strong double-digit growth in both revenue and profit for the first quarter of FY27 compared to the same period last year.
Why it mattersThe results demonstrate the company's ability to grow its ratings business through bank credit demand even when the corporate bond market is muted, while successfully diversifying into ESG and global sovereign ratings.
Consolidated Operating Income (Q1): ₹111.68 CrConsolidated PAT (Q1): ₹32.99 CrYoY Revenue Growth: 18.9%YoY PAT Growth: 24.6%Consolidated EBITDA Margin: 31.0%Q1 Revenue vs TTM Revenue: 23.6%
📅 Short termThe stock may see positive sentiment due to the strong bottom-line growth and resilient margins despite macroeconomic headwinds in the bond market.
📈 Long termThe company's expansion into GIFT City and its leadership in the emerging ESG ratings market provide structural growth drivers beyond traditional credit ratings.
⚠ Risk flags
- Cyclicality of corporate bond issuances
- Potential impact of El Niño on domestic economic growth
- High dependence on regulatory mandates
Key Highlights
Consolidated Operating Income grew 18.9% YoY to ₹111.68 Cr in Q1 FY27.
Consolidated PAT increased by 24.6% YoY to ₹32.99 Cr, with a PAT margin of 26.1%.
Ratings business revenue rose 19.1% YoY to ₹98.71 Cr despite a sharp 29.3% drop in market-wide corporate bond issuances.
Non-ratings business revenue grew 17.9% YoY to ₹12.97 Cr, now a key diversification pillar.
CARE ESG Ratings maintained a dominant 58% market share in the Category 1 ERP (Issuer Pay's Model) segment.
👀 What to Watch
Investors should monitor the sustainability of margins as the company scales its non-rating businesses and track the recovery of the corporate bond market, which remains a high-margin segment.
18.9% Revenue Growth in Q1 FY27; Consolidated PAT up 24.6% to ₹32.99 Cr
CARE Ratings reported a strong start to FY27 with consolidated operating income growing 18.9% YoY to ₹111.68 Cr. Despite a 29.3% decline in the broader corporate bond market, the company's ratings business grew 19.1% YoY, supported by robust bank credit growth of 18.6%. Profitability improved significantly, with consolidated PAT rising 24.6% to ₹32.99 Cr and EBITDA margins reaching 31.0%. The non-ratings segment, including analytics and ESG, contributed ₹12.97 Cr, maintaining its growth trajectory.
Confidence: HIGH
What changedThe company demonstrated strong financial resilience by growing its ratings business and margins despite a sharp contraction in the domestic corporate bond market.
Why it mattersThe results validate CARE's ability to capture revenue from bank loan ratings and non-rating segments, reducing its historical dependence on the volatile corporate bond market.
Consolidated Operating Income (Q1): ₹111.68 CrConsolidated PAT (Q1): ₹32.99 CrEBITDA Margin (Consolidated): 31.0%Non-Ratings Revenue Share: 11.6%Corporate Bond Issuance Growth: -29.3%
📅 Short termThe stock may see positive sentiment due to margin expansion and growth outperforming the underlying bond market trends.
📈 Long termStructural shifts towards non-rating services (ESG, Analytics) and global expansion through GIFT City and African subsidiaries provide a diversified growth engine.
⚠ Risk flags
- High dependence on bank credit growth
- Sensitivity to interest rate cycles
- Potential impact of El Niño on domestic economic growth
Key Highlights
Consolidated Operating Income grew 18.9% YoY to ₹111.68 Cr in Q1 FY27
Consolidated PAT increased by 24.6% YoY to ₹32.99 Cr
Ratings business revenue rose 19.1% YoY to ₹98.71 Cr despite a 29.3% drop in corporate bond issuances
Non-ratings business (Analytics, ESG, Consulting) contributed ₹12.97 Cr, up 17.9% YoY
Bank credit growth accelerated to 18.6% YoY, providing a strong tailwind for the ratings business
👀 What to Watch
Monitor the recovery in corporate bond issuances and the continued scaling of the non-ratings business, particularly ESG and Analytics. Watch for the impact of interest rate cycles on bank credit offtake, which is currently the primary driver of ratings revenue.
16.5% YoY Revenue Growth in Q1 FY27; Standalone PAT at ₹33.88 Cr
CARE Ratings reported a steady Q1 FY27 with standalone revenue from operations growing 16.5% YoY to ₹88.15 Cr. Standalone Net Profit increased by 16.3% YoY to ₹33.88 Cr, despite a significant 42.9% rise in other expenses. The company's international subsidiaries contributed ₹8.61 Cr to the consolidated revenue. EPS for the quarter improved to ₹11.27 from ₹9.72 in the previous year's corresponding quarter.
Confidence: HIGH
What changedThe filing represents the release of unaudited financial results for the first quarter of the 2026-27 fiscal year.
Why it mattersThe results demonstrate resilient growth in a seasonally slower quarter, maintaining double-digit top-line and bottom-line expansion despite broader market headwinds in corporate bond issuances.
Standalone Revenue (Q1 FY27): ₹88.15 CrStandalone PAT (Q1 FY27): ₹33.88 CrYoY Revenue Growth: 16.5%Q1 Revenue vs TTM Revenue: ~18.6%Subsidiary Revenue Contribution: ₹8.61 Cr
📅 Short termThe stock may see neutral to positive sentiment as the company maintained its growth momentum and margins in a challenging credit environment.
📈 Long termStructural growth depends on the successful scaling of non-rating subsidiaries and the recovery of the private capex cycle leading to higher bond issuances.
⚠ Risk flags
- Rising operating costs (Other expenses up 42.9% YoY)
- Sensitivity to corporate bond market volumes
- Dependence on regulatory mandates for credit ratings
Key Highlights
Standalone Revenue from operations grew 16.5% YoY to ₹88.15 Cr from ₹75.64 Cr.
Standalone Net Profit rose 16.3% YoY to ₹33.88 Cr compared to ₹29.12 Cr in Q1 FY26.
Other expenses increased significantly by 42.9% YoY to ₹12.54 Cr.
International subsidiaries (3 units) contributed ₹8.61 Cr to total consolidated revenue.
The company allotted 13,400 equity shares during the quarter under its ESOP 2020 scheme.
👀 What to Watch
Investors should monitor the growth trajectory of non-rating segments like Analytics and ESG, and track corporate bond issuance volumes which typically influence the core rating business.
CARE Ratings Approves Rs 14 Final Dividend; Total FY26 Payout Reaches Rs 22 Per Share
CARE Ratings held its 33rd Annual General Meeting on July 03, 2026, where shareholders approved all proposed resolutions with near-unanimous support (over 99.99%). A final dividend of Rs 14 per share was declared, which, combined with the Rs 8 interim dividend, brings the total payout for FY26 to Rs 22 per share. Key administrative approvals included the re-appointment of Mr. Mehul Pandya as Director and M/s. B S R & Co. LLP as Statutory Auditors. The company maintains a strong financial profile with a TTM PAT of Rs 173 Cr and an operating margin of 41.6%.
Confidence: HIGH
What changedShareholders have formally ratified the FY26 financial results, the final dividend distribution, and the continuation of key leadership and auditing partners.
Why it mattersThe high approval ratings (99.99%+) indicate strong shareholder confidence in the current management and the 'Quality Led Growth' strategy, while the dividend provides a tangible yield to investors.
Final Dividend: Rs 14 per shareTotal FY26 Dividend: Rs 22 per shareDividend Yield (Approx): 1.32%TTM Revenue: Rs 473 CrOperating Profit Margin: 41.6%
📅 Short termThe stock may see neutral to positive sentiment as the final dividend is confirmed, providing clarity on the total yield for the previous fiscal year.
📈 Long termLimited structural impact as this was a routine AGM; however, the re-appointment of leadership ensures continuity in the company's expansion into GIFT City and global markets.
Key Highlights
Final dividend of Rs 14 per share approved, bringing total FY26 dividend to Rs 22 per share
Resolution to adopt FY26 Audited Financial Statements passed with 99.9991% votes in favor
Mr. Mehul Pandya re-appointed as Director with 99.9989% shareholder approval
Statutory Auditors B S R & Co. LLP re-appointed with 99.9961% of valid votes cast
Non-rating segments like Analytics and ESG now contribute 11% to the total revenue
👀 What to Watch
Investors should note the final dividend payout and monitor the company's diversification into non-rating segments to offset volatility in corporate bond issuances.
CARE Ratings Appoints 16-Year Veteran Sanjay Agarwal as Chief Risk Officer
CARE Ratings has announced the appointment of Mr. Sanjay Agarwal as Chief Risk Officer (CRO), effective August 1, 2026. Mr. Agarwal is an internal promotion, having served the company for 16 years and currently holding the position of Senior Director. He brings over 30 years of experience in financial services, specializing in risk management and credit analysis. This leadership transition occurs as the company maintains a high operating profit margin of 41.6% and navigates a challenging environment where corporate bond issuances declined by 37% in Q2 FY26.
Confidence: HIGH
What changedMr. Sanjay Agarwal, a long-term internal leader, has been designated to take over the Chief Risk Officer role starting August 2026.
Why it mattersFor a credit rating agency, the CRO is vital for maintaining the analytical integrity and regulatory compliance that sustain its competitive moat and 'Quality Led Growth' strategy.
Experience: 30+ yearsCompany Tenure: 16 yearsEffective Date: August 1, 2026TTM Revenue: ₹473 CrOperating Profit Margin: 41.6%
📅 Short termThe announcement is unlikely to impact the stock price in the short term as the effective date is over a year away and involves an internal promotion.
📈 Long termThe appointment suggests a focus on continuity and internal expertise, which is crucial for maintaining the company's reputation in the highly regulated credit rating industry.
Key Highlights
Appointment of Mr. Sanjay Agarwal as Chief Risk Officer effective August 1, 2026
Appointee brings over 30 years of experience in the financial services sector
Internal candidate with a 16-year tenure at CARE Ratings
Currently serves as Senior Director within the organization
Company maintains a strong TTM PAT of ₹173 Cr and ROCE of 25.0%
👀 What to Watch
Monitor for any updates to credit rating methodologies or risk frameworks following the transition in August 2026, particularly as the company expands into ESG and analytics.
CARE Ratings FY26 PAT up 24% to ₹173.7 Cr; AGM Scheduled for July 3, 2026
CARE Ratings Limited has announced its 33rd Annual General Meeting for July 3, 2026, following a strong financial performance in FY 2025-26. The company reported an 18% growth in revenue to ₹473.07 crore and a 24% increase in PAT to ₹173.70 crore. Profitability remains robust with an EBITDA margin of 42% and a PAT margin of 33%. Additionally, the company has fixed June 26, 2026, as the record date for dividend payments.
Key Highlights
Revenue from operations increased 18% YoY to ₹473.07 crore for FY 2025-26.
Profit After Tax (PAT) grew by 24% to ₹173.70 crore with an EPS of ₹57.06.
Maintains a dominant 58% market share in the ESG ratings (Category 1, Issuer-pays) segment.
CareEdge Global expanded sovereign rating coverage to 45 countries, representing 85% of global GDP.
Dividend record date and e-voting cut-off set for June 26, 2026.
👀 What to Watch
Investors should ensure they hold shares by the June 26 record date to qualify for the dividend. The strong margin profile and successful global expansion into sovereign ratings suggest a positive long-term outlook for the stock.
Madras High Court Vacates Asset Alienation Injunction Against CARE Ratings
The Madras High Court has vacated an injunction order dated February 1, 2023, which had previously restrained CARE Ratings from alienating its assets. The vacation of this order on June 3, 2026, follows the company's compliance with court requirements to provide adequate security. This development restores the company's full control over its asset base, although the security was provided without prejudice to the company's ongoing legal appeals.
Key Highlights
Madras High Court vacated the injunction restraining asset alienation on June 3, 2026.
The original injunction had been in place since February 1, 2023, pending provision of security.
CARE Ratings complied with the security requirements to facilitate the lifting of the restriction.
The company received the formal court order on June 4, 2026.
Compliance was performed without prejudice to the company's rights in its ongoing appeals.
👀 What to Watch
Investors should view this as a positive development that removes a significant legal restriction on the company's balance sheet flexibility. Continue to monitor the final outcome of the underlying legal appeals.
CARE Ratings Reports Strong FY26 Performance with 24% PAT Growth and Rs. 14 Final Dividend
CARE Ratings delivered a robust performance for FY26, with consolidated revenue growing 18% YoY to Rs. 473.07 crore and PAT increasing 24% YoY to Rs. 173.69 crore. The company maintained strong profitability, with consolidated EBITDA margins expanding to 42% for the full year. A final dividend of Rs. 14 per share has been recommended, bringing the total dividend for FY26 to Rs. 22 per share. Growth was well-distributed, with the core ratings segment growing 17% and the non-ratings segment increasing by 19%.
Key Highlights
Consolidated PAT for FY26 rose 24% YoY to Rs. 173.69 crore, marking an all-time high.
Consolidated Revenue from Operations increased 18% YoY to Rs. 473.07 crore in FY26.
Recommended a final dividend of Rs. 14 per share, resulting in a total annual dividend of Rs. 22.
Consolidated EBITDA grew by 27% YoY to Rs. 197.39 crore with a margin of 42%.
Non-ratings segment revenue grew by 19% YoY to Rs. 50.01 crore, contributing 11% to total revenue.
👀 What to Watch
Investors should take note of the significant margin expansion and the company's successful diversification into non-rating segments. The high dividend yield and strong cash flow generation make it an attractive pick for long-term portfolios.
CARE Ratings Recommends ₹14 Dividend and Reports Audited FY26 Results
CARE Ratings has announced a final dividend of ₹14 per share for the financial year 2026, with the record date fixed for June 26, 2026. The Board approved the audited financial results for FY26 with an unmodified opinion from auditors B S R & Co. LLP. The company also granted 55,000 ESOPs at an exercise price of ₹1,590 per share. Furthermore, the management provided an update on the pending stake sale of its IFSC subsidiary to SBI and NSE IFSC, noting that legal documentation is taking longer than expected.
Key Highlights
Recommended a final dividend of ₹14 per equity share for FY26, with a record date of June 26, 2026.
Granted 55,000 stock options to eligible employees at an exercise price of ₹1,590 per share.
Re-appointed B S R & Co. LLP as Statutory Auditors for a five-year term ending in 2031.
Reported delays in the partial stake sale of CareEdge Global IFSC Limited to SBI and NSE IFSC due to prolonged legal discussions.
The 33rd Annual General Meeting (AGM) is scheduled for July 3, 2026, via video conferencing.
👀 What to Watch
Investors should benefit from the healthy ₹14 dividend payout and should monitor the eventual completion of the IFSC subsidiary stake sale to marquee partners like SBI.
CARE Ratings Recommends ₹14 Final Dividend and Re-appoints Statutory Auditors
CARE Ratings has recommended a final dividend of ₹14 per equity share for the financial year 2026, with the record date set for June 26, 2026. The company also approved the re-appointment of B S R & Co. LLP as statutory auditors for a five-year term until 2031. Additionally, 55,000 stock options were granted to employees at an exercise price of ₹1,590 per share. The company reported a delay in the partial stake sale of its subsidiary, CareEdge Global IFSC Limited, to SBI and NSE IFSC due to ongoing legal documentation.
Key Highlights
Recommended a final dividend of ₹14 per equity share (Face Value ₹10) for FY26.
Re-appointed B S R & Co. LLP as Statutory Auditors for a 5-year term (2026-2031).
Granted 55,000 ESOPs under the 2020 scheme at an exercise price of ₹1,590.
Partial stake sale of CareEdge Global IFSC to SBI and NSE IFSC is still under negotiation due to documentation delays.
👀 What to Watch
Investors should ensure they hold shares by the June 26 record date to qualify for the ₹14 dividend. Monitor the eventual closure of the subsidiary stake sale to SBI and NSE IFSC as a potential catalyst for the stock.
CARE Ratings Declares ₹14 Dividend and Grants 55,000 ESOPs at ₹1,590 Exercise Price
CARE Ratings has recommended a final dividend of ₹14 per share for FY26, with the record date set for June 26, 2026. The company also approved the grant of 55,000 stock options to employees at an exercise price of ₹1,590 per share, vesting over three years. Additionally, the board provided an update on the delayed partial stake sale of its subsidiary, CareEdge Global IFSC Limited, to SBI and NSE IFSC, confirming that negotiations are still active. B S R & Co. LLP has been re-appointed as the statutory auditor for a five-year term.
Key Highlights
Recommended a final dividend of ₹14 per equity share (Face Value ₹10) for FY26.
Granted 55,000 stock options under the 2020 ESOP scheme at an exercise price of ₹1,590.
Set June 26, 2026, as the record date for dividend eligibility.
Re-appointed B S R & Co. LLP as Statutory Auditors for a five-year term until 2031.
Confirmed ongoing negotiations for the stake sale in CareEdge Global IFSC Limited to SBI and NSE IFSC.
👀 What to Watch
Investors should note the ₹14 dividend and the June 26 record date for eligibility. Monitor the eventual closure of the subsidiary stake sale to SBI and NSE as a potential valuation catalyst.
CARE Ratings Recommends ₹14 Final Dividend; Sets June 26 as Record Date
CARE Ratings has announced a final dividend of ₹14 per share for the financial year 2026, subject to shareholder approval at the upcoming AGM. The company has fixed June 26, 2026, as the record date for determining eligibility for this payout. In addition to the dividend, the board approved the grant of 55,000 stock options at an exercise price of ₹1,590. Investors should also note that the proposed partial stake sale of its subsidiary, CareEdge Global IFSC Limited, to SBI and NSE IFSC is experiencing delays due to prolonged legal negotiations.
Key Highlights
Recommended a final dividend of ₹14 per equity share (140% of face value) for FY26.
Fixed June 26, 2026, as the record date for the dividend payment.
Approved the grant of 55,000 stock options under the 2020 ESOP scheme at an exercise price of ₹1,590.
Re-appointed B S R & Co. LLP as Statutory Auditors for a five-year term until 2031.
Reported that negotiations for the stake sale in CareEdge Global IFSC Limited to SBI and NSE IFSC are ongoing but delayed.
👀 What to Watch
Investors interested in the dividend should ensure they hold the stock before the June 26 record date. Monitor the progress of the subsidiary stake sale as it remains a key corporate development for value unlocking.
CARE Ratings Recommends ₹14 Final Dividend and Reports FY26 Results; Subsidiary Stake Sale Delayed
CARE Ratings has recommended a final dividend of ₹14 per share for FY26, following the approval of its annual audited financial results. The company has set June 26, 2026, as the record date for the dividend payment, which is subject to shareholder approval at the AGM on July 3, 2026. The board also approved the grant of 55,000 ESOPs at an exercise price of ₹1,590 per share. However, the company noted a delay in the partial stake sale of its subsidiary, CareEdge Global IFSC Limited, to SBI and NSE IFSC due to ongoing legal negotiations.
Key Highlights
Recommended a final dividend of ₹14 per equity share for the financial year ended March 31, 2026.
Set June 26, 2026, as the record date for dividend eligibility.
Approved the grant of 55,000 stock options under the 2020 ESOP scheme at an exercise price of ₹1,590.
Reported a delay in the partial stake sale of subsidiary CareEdge Global IFSC Limited to SBI and NSE IFSC.
Re-appointed B S R & Co. LLP as statutory auditors for a five-year term until 2031.
👀 What to Watch
Investors should track the record date of June 26 to qualify for the ₹14 dividend and monitor updates regarding the strategic stake sale to SBI and NSE.
CARE Ratings Recommends ₹14 Final Dividend; Delays Stake Sale in Subsidiary
CARE Ratings has recommended a final dividend of ₹14 per equity share for the financial year ended March 31, 2026. The company has set June 26, 2026, as the record date for the dividend, which is subject to shareholder approval at the upcoming AGM on July 3, 2026. Additionally, the board approved the grant of 55,000 ESOPs at an exercise price of ₹1,590 per share. Investors should note that the proposed partial stake sale of its subsidiary, CareEdge Global IFSC Limited, to SBI and NSE IFSC has been delayed due to prolonged legal negotiations.
Key Highlights
Recommended a final dividend of ₹14 per equity share of face value ₹10 each.
Record date for dividend payment fixed as June 26, 2026.
Approved grant of 55,000 stock options to employees at an exercise price of ₹1,590.
Re-appointed B S R & Co. LLP as statutory auditors for a five-year term until 2031.
Reported a delay in the partial stake sale of CareEdge Global IFSC Limited to SBI and NSE IFSC.
👀 What to Watch
Investors may consider holding the stock to benefit from the ₹14 dividend payout while monitoring the eventual completion of the subsidiary stake sale to SBI and NSE.
CARE Ratings & NSE Commercially Launch PaRRVA for Investment Performance Verification
CARE Ratings, in collaboration with the National Stock Exchange (NSE), has commercially launched PaRRVA, a SEBI-conceptualized framework for verifying investment performance. The platform provides independent validation of risk-return metrics for Investment Advisors, Research Analysts, and Trading Members using authenticated market data. By computing nearly 50 different risk and return matrices, PaRRVA aims to eliminate selective performance reporting and enhance transparency in the financial advisory ecosystem. This initiative represents a significant expansion of CARE Ratings' service portfolio into the regulatory compliance and financial analytics space.
Key Highlights
Commercial launch of PaRRVA (Past Risk and Return Verification Agency) following a pilot project initiated in December 2025.
Platform computes nearly 50 different risk and return metrics using transaction data directly from stock exchanges and clearing corporations.
Features T+1 portfolio validation and end-of-day checks for intraday strategies to ensure high data accuracy and speed.
NSE acts as the PaRRVA Data Centre (PDC), providing the necessary infrastructure for authenticated market data.
The framework is designed to prevent selective returns presentation and client-specific claims by financial intermediaries.
👀 What to Watch
Investors should monitor the adoption rate of PaRRVA among financial intermediaries as it establishes a new, high-credibility revenue stream for CARE Ratings. This move strengthens the company's competitive moat in the analytical and regulatory services sector beyond traditional credit ratings.
CARE Ratings to Launch PaRRVA Services from May 4, 2026, Following SEBI Authorization
CARE Ratings Limited has received final authorization from SEBI to commence operations as a Past Risk and Return Verification Agency (PaRRVA) starting May 4, 2026. This follows the successful completion of a pilot phase and initial recognition granted in December 2025. The new service line, established under SEBI's April 2025 framework, allows the company to verify historical performance data for market participants. This development represents a strategic expansion of CARE's service portfolio into regulated verification services.
Key Highlights
Authorized by SEBI to begin PaRRVA services effective from May 4, 2026
Authorization follows the successful completion of a pilot-phase mandated by SEBI
Initial recognition as a verification agency was previously received on December 5, 2025
Service governed under the regulatory framework of SEBI Circular dated April 4, 2025
👀 What to Watch
Investors should monitor the contribution of this new service line to the company's non-rating revenue in future quarterly results. The expansion into verification services provides a diversified revenue stream and strengthens the company's regulatory standing.
CARE Ratings to Form 50:50 JV 'Operus Limited' for GCC Services with Rs 22.5 Cr Investment
CARE Ratings has approved the incorporation of a joint venture named 'Operus Limited' in partnership with Vestian Global Work Place Services. The JV will focus on Global Capability Centre (GCC) enablement services, assisting global enterprises in designing and operating GCCs in India. CARE Ratings will invest approximately Rs 22.5 crores for a 50% equity stake in the new entity. The incorporation is expected to be completed by June 30, 2026, subject to receiving a No-Objection Certificate from SEBI.
Key Highlights
Formation of a 50:50 Joint Venture with Vestian Global Work Place Services Private Limited.
Initial equity capital contribution of Rs 22.5 crores by CARE Ratings at face value.
Target entity 'Operus Limited' will provide end-to-end GCC solutions including strategy, talent, and workspace setup.
The incorporation process is tentatively scheduled for completion by June 30, 2026.
The venture marks a strategic diversification into the high-growth Global Capability Centre enablement sector.
👀 What to Watch
Investors should view this as a positive diversification move that leverages CARE's brand into the consulting and managed services space. Monitor the progress of SEBI approvals and the subsequent scale-up of the GCC enablement business.
CARE Ratings Subsidiary Receives ESG Rating License from IFSCA
CARE Ratings' wholly-owned subsidiary, CareEdge Global IFSC Limited, has successfully obtained a license from the International Financial Services Centres Authority (IFSCA) on March 11, 2026. This license permits the subsidiary to operate as an ESG Rating and Data Product Provider within the International Financial Services Centre. This strategic move allows the company to enter the rapidly growing global market for Environmental, Social, and Governance (ESG) assessments. The expansion diversifies the company's revenue streams beyond traditional credit rating services.
Key Highlights
Wholly-owned subsidiary CareEdge Global IFSC Limited received the IFSCA license on March 11, 2026.
Authorized to function as an ESG Rating and Data Product Provider in the IFSC.
Positions CARE Ratings to capture demand in the specialized global ESG services market.
The license represents a regulatory milestone for the company's international service offerings.
👀 What to Watch
Investors should view this as a positive long-term growth driver that diversifies the company's portfolio. Monitor the scale of operations and revenue contribution from this new ESG vertical in future earnings reports.
CARE Ratings Reports Strong Q3 FY26 Performance with 24% YoY Growth in Consolidated PAT
CARE Ratings Limited reported a robust performance for 9M FY26, with consolidated revenue from operations growing 17% YoY to Rs. 342.40 crore. Profitability saw a significant jump as consolidated PAT rose 24% YoY to Rs. 120.25 crore, driven by operational efficiencies and a 46% standalone EBITDA margin. While the ratings segment remains the core contributor at 89% of revenue, the non-ratings segment showed faster growth at 21% YoY. Despite a 11% decline in corporate bond issuances during Q3, the company benefited from a 14.5% increase in bank credit offtake.
Key Highlights
Consolidated PAT for 9M FY26 grew by 24% YoY to Rs. 120.25 crore with a 32% margin.
Consolidated revenue from operations for 9M FY26 increased 17% YoY to Rs. 342.40 crore.
Standalone EBITDA margin stood at a healthy 46% for 9M FY26, up from 44% in the previous year.
Non-ratings segment revenue grew by 21% YoY to Rs. 36.71 crore, contributing 11% to total revenue.
Bank credit offtake accelerated to 14.5% growth as of December 2025, supporting rating volumes.
👀 What to Watch
Investors should view the strong margin expansion and growth in non-rating segments as positive indicators of business diversification and efficiency. The stock remains a play on the Indian credit cycle and private capex revival, though moderation in bond issuances is a factor to watch.
CARE Ratings Q3 Net Profit Jumps 29% YoY to ₹35.9 Crore; Revenue Up 16%
CARE Ratings reported a strong year-on-year performance for the quarter ended December 31, 2025, with consolidated net profit rising 29.1% to ₹35.9 crore. Revenue from operations grew by 16.3% YoY to ₹112.1 crore, reflecting steady demand in the credit rating and analytics business. While sequential performance showed a decline from the September quarter, the nine-month (9M FY26) net profit remains robust at ₹118.3 crore, a 25% increase over the previous year. The company continues to manage its cost base effectively despite a rise in employee benefit expenses.
Key Highlights
Consolidated Revenue from operations increased 16.3% YoY to ₹112.12 crore in Q3 FY26.
Net Profit attributable to owners grew 29.1% YoY to ₹35.90 crore from ₹27.80 crore.
9M FY26 Net Profit reached ₹118.34 crore, up 25% compared to ₹94.63 crore in 9M FY25.
Total expenses for the quarter rose to ₹76.12 crore, with employee costs accounting for ₹55.13 crore.
Other income remained a significant contributor at ₹12.99 crore for the quarter.
👀 What to Watch
Investors should view the strong year-on-year growth as a positive indicator of the company's market position. The stock remains a key beneficiary of the expanding Indian corporate bond market and credit growth.
